Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 12/2019

Open Access 01-11-2019 | Sarcoidosis | Review Article

Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic review

Authors: Luz Kelly Anzola, Andor W. J. M. Glaudemans, Rudi A. J. O. Dierckx, F. Andres Martinez, Sergio Moreno, Alberto Signore

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2019

Login to get access

Abstract

Objective

To review the literature on the clinical application of radiolabeled somatostatin receptor scintigraphy (SRS) by SPECT and PET in adults with chronic inflammatory diseases.

Research design

Systematic review of published observational studies between 1993 and 2017.

Data collection and analysis

The Cochrane Central Register of Controlled Trials, MedLine, EMBASE, PubMed, Google Scholar, OVID, EBSCO, Scopus, and Web of Science were used to search for studies on the use of SRS in adults with chronic inflammatory diseases. A team of reviewers independently screened for eligible studies. Quality of evidence was assessed by QUADAS approach.

Results

Eligible papers included 38 studies. Studied populations were heterogeneous, and patients were classified according to the diagnosed disease: endothelial inflammation, rheumatoid arthritis, cardiac allograft rejection, granulomatous diseases, small vessel vasculitis, idiopathic pulmonary fibrosis, sarcoidosis, and thyroid exophthalmopathy. Because of many quality differences between studies, it was not possible to pool data, and a narrative synthesis is reported.

Conclusion

Results highlight the value of SRS to detect active inflammation in several chronic inflammatory conditions, despite the bias related to the index test, showing lack of standardization of the scintigraphic technique and high variability of methods used to clinically evaluate inflammatory condition.
Literature
1.
Chianelli M, Parisela M, DÁlessandria C, et al. The developing role of peptide radiopharmaceuticals in the study of chronic inflammation: new techniques for novel therapeutic options. Q J Nucl Med. 2003;47:256–69.PubMed
2.
Chianelli M, Mather SJ, Martin-Comin J, et al. Radiopharmaceuticals for the study of inflammatory processes. A review. Nucl Med Commun. 1997;18:437–55.CrossRefPubMed
3.
Anzola LK, Galli F. Dierck RA. SPECT radiopharmeceuticals for imaging chronic inflammatory diseases in the last decade. Q J Nucl Med Mol Imaging. 2015;59:197–213.PubMed
4.
5.
Cascini GL, Cuccurullo V, Tamburrini O, et al. Peptide imaging with somatostatin analogues: more than cancer probes. Curr Radiopharm. 2013;6:36–40.CrossRefPubMed
6.
Sosabowski J, Melendez A, Mather S. Radiolabelling of peptides for diagnosis and therapy of non-oncological disease. Q J Nucl Med. 2003;43:223–37.
7.
Rambaldi PF, Cuccurullo V, Briganti V. The present and future role of 111In pentetreotide in the PET era. Q J Nucl Med Mol Imaging. 2005;49(3):225–35.PubMed
8.
Brazeau P, Vale WW, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;5(179):77–9.CrossRef
9.
Patel YC, Reichlin S. Somatostatin in hypothalamus, extrahypothalamic brain, and peripheral tissues of the rat. Endocrinology. 1978;102:523–30.CrossRefPubMed
10.
Narayanan S, Kunz PL. Role of somatostatine analogues in the treatment of neuroendocrine tumors. J Natl Compr Cancer Netw. 2015;13:109–17.CrossRef
11.
Duet M, Liote F. Somatostatine and somatostatine analog scintigraphy: any benefits for rheumatology patients? Joint Bone Spine. 2004;71:530–5.CrossRefPubMed
12.
Cascini GL, Cuccurullo V, Mansi L. The non tumor uptake of 111In octreotide creates new clinical indications in benign diseases, but also in oncology. Q J Nucl Med Mol Imaging. 2010;54:24–36.PubMed
13.
Wouter AP, de Blois E, Chan HS, et al. 68Ga-labeled DOTA-peptides and 68Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med. 2011;41:314–21.CrossRef
14.
15.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.CrossRefPubMed
16.
Higgins JPTAD, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews.
17.
Whitting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.CrossRef
18.
Tarkin JM, Joshi FR, Evans NR, et al. Detection of atherosclerotic inflammation by 68Ga-DOTATATE PET compared to 18FFDG PET imaging. J Am Coll Cardiol. 2017;69(14):774–91.CrossRef
19.
Malmberg C, Ripa RS, Johnbeck CB, et al. 64Cu-DOTATATE for noninvasive assessment of atherosclerosis in large arteries and its correlation with risk factors: head-to-head comparison with 68Ga-DOTATOC in 60 patients. J Nucl Med. 2015;56:1895–900.CrossRefPubMed
20.
21.
Wan SMY, Endozo R, Michopoulou S, et al. PET/CT imaging of unstable carotid plaque with 68 Ga-labeled somatostatin receptor ligand. J Nucl Med. 2017;58:774–80.CrossRefPubMed
22.
Pedersen SF, Sandholt VB, Keller SH, et al. 64Cu-DOTA-TATE PET/MRI for detection of activated macrophages in carotid atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2015;35:1696–703.CrossRefPubMedPubMedCentral
23.
Li X, Samnick S, Lapa C, et al. 68Ga-DOTA-TATE PET/CT for the detection of inflammation of large arteries: correlation with 18F-FDG, calcium burden and risk factors. EJNMMI Res. 2012;2:52–62.CrossRefPubMedPubMedCentral
24.
Mojtahedi A, Alavi A, Thamake S, et al. Assessment of vulnerable atherosclerotic and fibrotic plaques in coronary arteries using 68Ga-DOTATATE PET/CT. Am J Nucl Med Mol Imaging. 2015;5(1):65–71.PubMed
25.
Rominger A, Saam T, Vogl E, et al. In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J Nucl Med. 2010;51:193–7.CrossRefPubMed
26.
27.
Armani C, Catalani E, Balbarini A, et al. Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J Leukoc Biol. 2007;81:845–55.CrossRefPubMed
28.
Rinne P, Hellberg S, Kiugel M, et al. Comparison of somatostatin receptor 2-targeting PET tracers in the detection of mouse atherosclerotic plaques. Mol Imaging Biol. 2016;18:99–108.CrossRefPubMed
29.
Signore A, Anzola LK, Auletta S, et al. Current status of molecular imaging in inflammatory and autoimmune disorders. Curr Pharm Des. 2018;24:1–11.CrossRef
30.
Anzola LK, Chianelli M, Galli F, et al. Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary Sjögren’s syndrome treated with infliximab: a pilot study. EJNMMI Res. 2016;6(1):49–60.CrossRef
31.
Vanhagen PM, Markusse MH, Lamberts SWJ, et al. Somatostatin receptor imaging the presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum. 1994;37(10):1521–7.CrossRefPubMed
32.
Reubi JC, Waser B, Markusse HM, et al. Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. Eur J Pharmacol. 1994;271:371–8.CrossRefPubMed
33.
Malviya G, Signore A, Lagana B, et al. Radiolabelled peptides and monoclonal antibodies for therapy decision making in inflammatory diseases. Curr Pharm Des. 2008;14:2401–014.CrossRefPubMed
34.
Ambrosini V, Zompatori M, De Lucca F, et al. Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results. J Nucl Med. 2010;51:1950–5.CrossRefPubMed
35.
Lebtahi R, Moreau S, Marchan-Adam S, et al. Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med. 2006;47:1281–7.PubMed
36.
Win T, Screaton NJ, Porter J, et al. Novel positron emission tomography/computed tomography of diffuse parenchymal lung disease combining a labeled somatostatin receptor analogue and 2-deoxy-2 18F Fluoro-D-glucose. Mol Imaging. 2012;11(2):91–8.CrossRefPubMed
37.
Aguirre-Balsalobre F, Mengual-Verdu E, Muñoz-Acosta JM, et al. Octreotide scintigraphy in thyroid orbitopathy. Arch Soc Esp Oftalmol. 2007;82:133–40.PubMed
38.
Colao A, Lastoria S, Ferone D, et al. Clinical response to corticosteroid therapy in patients with graves ophthalmopathy. J Clin Endocrinol Metab. 1998;83:3790–4.PubMed
39.
Gerdin MN, Van der Zan FM, Van Royen EA, et al. Octreotide-scintigraphy is a disease-activity parameter in graves ophthalmopathy. Clin Endocrinol. 1999;50:373–9.CrossRef
40.
Kahaly G, Rainer G, Diaz M, et al. Indium-111-pentetreotide in Graves’ disease. J Nucl Med. 1998;39:553–36.
41.
Kahaly G, Diaz M, Hahn K, et al. Indium-111-Pentetreotide scintigraphy in Graves’ ophthalmopathy. J Nucl Med. 1995;36:550–4.PubMed
42.
Krassas GE, Doumas A, Kaltsas TH, et al. Somatostatin receptor scintigraphy before and after treatment with somatostatine analogues in patients with thyroid eye disease. Thyroid. 1999;9:47–52.CrossRefPubMed
43.
Krassas GE, Doumas A, Pontikides N, et al. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol. 1995;42:571–80.CrossRef
44.
Moncayo R, Balsissera I, Decristoforo C, et al. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatine analogue 111In-octreotide. Thyroid. 1997;7:21–9.CrossRefPubMed
45.
Nocaudie M, Bailliez A, Itti E, et al. Somatostatine receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy. Eur J Nucl Med. 1999;26:511–7.CrossRefPubMed
46.
Postema P, Krenning EP, Reubi JC, et al. 111In-DTPA-d-Phe1octreotide scintigraphy in thyroidal and orbital Graves’s disease: a parameter for disease activity? J Clin Endocrinol Metab. 1994;79:1845–51.CrossRefPubMed
47.
Burggasser G, Hurtl I, Hauff W, et al. Receptor tracer 99mTc-P829 in patients with Graves’ disease. J Nucl Med. 2003;44:1547–55.PubMed
48.
Sun H, Xu-Feng J, Wang S, et al. 99mTcHYNIC-TOC scintigraphy in evaluation of active Grave’s ophthalmopathy (GO). Endocrinol. 2007;31:305–10.
49.
Zhao R, Wang J, Deng J, Yang W, Wang J. Efficacy of 99mTcEDDA/HYNIC-TOC SPECT/CT scintigraphy in Graves’ ophthalmopathy. Am J Nucl Med Mol Imaging. 2012;2(2):242–7.PubMedPubMedCentral
50.
Lincke T, Singer J, Kluge R, et al. Relative quantification of indium-111 pentetreotide and gallium-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies. Thyroid. 2009;19:381–9.CrossRefPubMed
51.
Lapa C, Reiter T, Kircher M, et al. Somatostatine receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI. Oncotarget. 2016;7(47):77807–14.CrossRefPubMedPubMedCentral
52.
Kwekkeboom DJ, Krenning EP, Siang Kho G, et al. Somatostatine receptor imaging in patients with sarcoidosis. Eur J Nucl Med. 1998;25:1284–92.CrossRefPubMed
53.
Lebtahi R, Crestani B, Belmatoug N, et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med. 2001;42:21–6.PubMed
54.
Kampuis LS, Kwekkeboom DJ, Missotten TO, et al. Somatostatine receptor scintigraphy patterns in patients with sarcoidosis. Clin Nucl Med. 2015;40:925–9.CrossRef
55.
Gormsen LC, Haraldsen A, Kramer S, et al. A dual tracer 68-Ga-DOTANOC PET/CT and 18F-FDG PET/CT pilot study for detection of cardiac sarcoidosis. EJNMI Res. 2016;6:52–64.CrossRef
56.
Nobashi T, Nakamoto Y, Kubo T, et al. The utility of PET/CT with 68Ga-DOTATOC in sarcoidosis: comparison with Ga-scintigraphy. Ann Nucl Med. 2016;30:544–52.CrossRefPubMed
57.
Piotrowski WJ, Bienkiwicz M, Frieske I, et al. Somatostatine receptor scintigraphy in sarcoidosis: relation to selected clinical and laboratory markers. Polskie Archiwum Medycyny Wewnetrznej. 2012;122(3):98–105.PubMed
58.
Weinmann P, Crestani B, Tazi A, et al. 111In-pentreotide scintigraphy in patients with Langerhans’ cell histiocytosis. J Nucl Med. 2000;41:1808–12.PubMed
59.
Oztürk E, Günalp B, Ozgüven M, et al. The visualization of granulomatous disease with somatostatin receptor scintigraphy. Clin Nucl Med. 1994 Feb;19(2):129–32.CrossRefPubMed
60.
Vanhagen PM, Krenning EP, Reubi JC, Kwekkeboom DJ, Bakker WH, Mulder AH, et al. Somatostatine analogue scintigraphy in granulomatous disease. Eur J Nucl Med. 1994;21(6):497–502.CrossRefPubMed
61.
Aparici CM, Narula J, Puig M, et al. Somatostatin receptor scintigraphy predicts impending cardiac allograft rejection before endomyocardial biopsy. Eur J Nucl Med. 2000 Dec;27(12):1754–9.CrossRefPubMed
62.
Neumann I, Mirszaei S, Birck R, et al. Expression of somatostatin receptors in inflammatory lesions and diagnostic value of somatostatin receptor scintigraphy in patients with ANCA-associated small vessel vasculitis. Rheumatology. 2004;43:195–201.CrossRefPubMed
63.
Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982–93.CrossRefPubMed
64.
Pettinato C, Sarnelli A, Di Donna M, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35:72–9.CrossRefPubMed
65.
Borie R, Fabre A, Prost F, et al. Activation of somatostatin receptors attenuates pulmonary fibrosis. Thorax. 2008;63:251–8.CrossRefPubMed
66.
Breeman WAP, Martin Van Hagen P, Kwekkeboom DJ, Visser TJ, Krenning EP. Somatostatin receptor scintigraphy using 111In-DTPA-octreotide. Eur J Nucl Med. 1998;25:182–6.CrossRefPubMed
67.
Pérez Moreiras J, Coloma Bockos JE, Prada Sánchez MC. Orbitopatía tiroidea (fisiopatología, diagnóstico y tratamiento). Arch Soc Esp Oftalmol. 2003;78:407–31.CrossRefPubMed
68.
Jacobson DH, Gorman CA. Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis and treatment. Endocr Rev. 1984;5:200–20.CrossRefPubMed
69.
Colao A, Pivinello R, Lastoria S, et al. Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves’ disease. Eur J Endocrinol. 2000;143:S35–42.CrossRefPubMed
70.
Postema PTE, Kwekkeboom DJ, Van Hagen PM, et al. Somatostatin-receptor scintigraphy in Graves’s orbitopathy. Eur J Nucl Med. 1996;23:615–7.CrossRefPubMed
71.
Dalm VA, van Hagen PM, van Koetsveld PM, et al. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab. 2003;285:E344–53.CrossRefPubMed
72.
Khan MU, Khan S, El-Refaie S, et al. Clinical indications for Gallium-68 positron emission tomography imaging. Eur J Surg Oncol. 2009;35:561–7.CrossRefPubMed
73.
Vanhagen PM, Krenning EP, Reubi JC, et al. Somatostatin analogue scintigraphy in granulomatous disease. Eur J Nucl Med. 1994 Jun;21(6):497–502.CrossRefPubMed
74.
Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int. 1998;53:743–53.CrossRefPubMed
75.
Rao JK, Weinberger M, Oddone EZ, Allen NB, Landsman P, Feussner JR. The role of anti neutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Ann Intern Med. 1995;123:925–32.CrossRefPubMed
76.
Harper L, Savage CO. Pathogenesis of ANCA-associated systemic vasculitis. J Pathol. 2000;190:349–59.CrossRefPubMed
77.
Gephardt GN, Ahmad M, Tubbs RR. Pulmonary vasculitis (Wegener’s granulomatosis) immunohistochemical study of T and B cell markers. Am J Med. 1983;74:700–4.CrossRefPubMed
78.
Rasmussen N, Petersen J. Cellular immune responses and pathogenesis in c-ANCA positive vasculitides. J Autoimmun. 1993;6:227–36.CrossRefPubMed
79.
Ferrario F, Rastaldi MP. Necrotizing-crescentic glomerulonephritis in ANCA-associated vasculitis: the role of monocytes. Nephrol Dial Transpl. 1999;14:1627–31.CrossRef
Metadata
Title
Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic review
Authors
Luz Kelly Anzola
Andor W. J. M. Glaudemans
Rudi A. J. O. Dierckx
F. Andres Martinez
Sergio Moreno
Alberto Signore
Publication date
01-11-2019
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2019
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04489-z

Other articles of this Issue 12/2019

European Journal of Nuclear Medicine and Molecular Imaging 12/2019 Go to the issue

Image of the Month

Incidental pulmonary embolism detected on workup for Y-90 SIRT

Letter to the Editor

Letter to the editor: Use of radioactive iodine treatment in patients with hyperthyroidism? A case for shared decision making

Original Article

Assessment of acute bone loading in humans using [18F]NaF PET/MRI

Editorial

The 70th anniversary of automated radionuclide imaging

Editorial

Why wait for posterity (or the future) to provide proof to savor the elixir of precision oncology? Read interviews with intellects and dine with the doyens of discovery

Original Article

Clinical significance of quantitative assessment of right ventricular glucose metabolism in patients with heart failure with reduced ejection fraction